 | Up a level |
Journal Article
Kim, D., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., Solomon, B. J., Wolf, J., Thomas, M., Schuler, M., Liu, G., Santoro, A., Geraldes, M., Boral, A. L., Yovine, A. and Shaw, A. T. (2014). Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK plus ) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1. Int. J. Radiat. Oncol. Biol. Phys., 90. S. S33 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1879-355X
Thomas, M., Wolf, J., Schuler, M., Goldwasser, M., Boral, A. and Shaw, A. T. (2014). Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC. Oncol. Res. Treat., 37. S. 89 - 91. BASEL: KARGER. ISSN 2296-5262